Due to research and advances in antiepileptic medication, individuals with ULD can live up to 60 years of age. Nevertheless, severe myoclonus can lead to injury by falling and becoming reliant on a wheelchair. Research
Because PME is so rare it is hard to do studies specifically double blind studies used to test different antiepileptic drugs. The wide range of symptoms including the differing EEG makes studying the effects of the AEDs difficult. In ULD, oligonucleotide therapeutic strategies have been used to replace gene effects while in Sialidosis enzyme replacement therapy has been studied in mouse models. In Laforas disease metformin has been approved for treatment by the European commission. In MERRF bacterial proteins have been identified in treatment in mitochondrial diseases but further studies are needed. History
The first instance where myoclonus and its relationship to epilepsy was in 1822 by Prichard. Lundborg was the first to name progressive myoclonus epilepsy in 1903 due to his study of several Swedish families as well as research done by Heinrich Unverricht in 1891. However, ULD was not recognized as a disease until a century later due to the rarity of the disease. In 1911, Lafora identified Lafora bodies but believed to be part of ULD. Laforas genetics was not described until 1995. Specific disorders
Several conditions can cause progressive myoclonic epilepsy.
Abrasion may refer to:

Abrasion (dental), the loss of tooth structure by mechanical forces from a foreign element
Abrasion (medical), a wound consisting of superficial damage to the skin
Abrasion (mechanical), the process of scuffing, scratching, wearing down, marring, or rubbing away
Abrasion (geology), mechanical scraping of a surface by friction between moving particles

See also
Abrasion coast, a coastline that is characterised by the removal (abrasion) of material
Abrasives